Align Technology (NDAQ:ALGN) Rating Kept
Analysts at Stifel Nicolaus have $265.00 PT on Align Technology (NDAQ:ALGN). Stifel Nicolaus’s PT would suggest a potential upside of 3.35 % from the company’s previous close. The rating was disclosed in analysts note on Tuesday, 21 November.
NDAQ:ALGN is right now trading 0.36% higher at $256.43 as of 8:07 AM New York time. Align Technology’s stock is 0% in the last 200 days. It has underperformed the Standard & Poor’s 500 index, which has increased 6.00% in the same time.
Out of 10 analysts covering Align Technology, 11 rate it a Buy, 0 indicate a Hold while 0 suggest a Sell. The highest target is $90 and the lowest is $74 according to Thomson/First Call. The 12-month mean target is $82.8, which means downside potential of 67.71% over the current price.
Magee Thomson Investment Partners Llc had the largest stake with ownership of 180,200 shares as of Q2 2015 for 5.58% of the US long equity exposure. Goodman Financial Corp is another very bullish active investment manager who is owning 76,409 shares of Align Technology or 4.28% of their US long equity exposure. Furthermore, Insight Capital Research & Management Inc have 2.62% of their US long equity exposure invested in the company for 62,836 shares. The Minnesota-based fund Disciplined Growth Investors Inc Mn revealed it had bought so far a stake worth about 2.45% of the active investment manager’s stock portfolio in Align Technology. The Massachusetts-based fund Fernwood Investment Management Llc is also positive about the stock, possessing 1.10 million shares or 2.25% of their US long equity exposure.
Align Technology (NDAQ:ALGN) Profile
Align Technology, Inc. designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Express/Lite (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case).
Align Technology (NDAQ:ALGN) traded up 0.36% on 21 November, hitting $256.43. A total of 1.30M shares of the company’s stock traded hands. This is up from average of 1.16M shares. Align Technology has a 52 week low of $88.56 and a 52 week high of $258.88. The company has a market cap of $20.56B and a P/E ratio of 77.86.
Get the latest Align Technology (NDAQ:ALGN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Align Technology (NDAQ:ALGN) Buy Rating Kept by Stifel Nicolaus; With $265.00 Target appeared first on Octafinance.